化工社化工社 化学情報印刷レポート · 研究参考用
チカルシリン
チカルシリン · (2S,5R,6R)-6-[(2R)-2-カルボキシ-2-(チオフェン-3-イル)アセトアミド]-3,3-ジメチル-7-オキソ-4-チア-1-アザビシクロ[3.2.0]ヘプタン-2-カルボン酸 · (2S,5β)-6α-[[(R)-2-カルボキシ-2-(3-チエニル)アセチル]アミノ]-3,3-ジメチル-7-オキソ-4-チア-1-アザビシクロ[3.2.0]ヘプタン-2β-カルボン酸 · 6α-[[(R)-カルボキシ-3-チエニルアセチル]アミノ]ペニシラン酸 · (R)-チカルシリン · Temocillin Disodium · icarcillin · TICARCILLIN
識別子と物理属性
| CAS No. | 34787-01-4 |
|---|---|
| 分子式 | C15H16N2O6S2 |
| 平均分子量 | 384.4 g/mol |
| 単同位体質量 | 384.04497858 g/mol |
| SMILES | CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O |
| InChIKey | OHKOGUYZJXTSFX-KZFFXBSXSA-N |
| PubChem CID | 36921 |
| ChEMBL | CHEMBL1449 |
| ChEBI | CHEBI:9587 |
| EC No. | 252-213-5 |
| DTXSID | DTXSID0023668 |
| 現地名 | チカルシリン |
化学・物理的性質
| XLogP | 0.8 |
|---|---|
| 極性表面積 | 178 |
| 水素結合供与体数 | 3 |
| 水素結合受容体数 | 8 |
| 回転可能結合数 | 5 |
| 重原子数 | 25 |
| 形式電荷 | 0 |
| 複雑度 | 640 |
| 医薬品 | Pharmaceuticals -> AntibioticsPharmaceuticals -> Listed in ZINC15 |
| 溶解度 | 7.16e-02 g/L |
| Human Drugs | Breast FeedingLactationMilk, HumanAnti-Infective AgentsAntibacterial AgentsPenicillins |
| Physical Description | Solid |
| 沸点 | 768.3±60.0 °C(Predicted) |
| 密度 | 1.62±0.1 g/cm3(Predicted) |
| 貯蔵条件 | 2-8°C |
| pKa（酸解離定数） | pKa 2.89±0.05(H2O t=25.0 I=0.15 (KCl)) (Uncertain)3.28±0.04 (Uncertain) |
| CAS データベース | 34787-01-4(CAS DataBase Reference) |
安全性と法規制
| GHS 分類 | DangerH317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 40 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| その他の安全情報 | IMAP assessments - 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(carboxy-3-thienylacetyl)amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]-: Environment tier I assessment |
| Hazard Classes and Categories | Skin Sens. 1 (100%) |
| Hepatotoxicity | Intravenous ticarcillin therapy has been associated with mild and transient serum aminotransferase elevations that were generally self-limited and only slightly more common with ticarcillin than with comparative antibiotics. Much more commonly reported were instances of anicteric hepatic injury from carbenicillin, a similar carboxypenicillin with extend coverage against Pseudomonas. Persons receiving high doses of intravenous carbenicillin not uncommonly (15% to 30%) developed serum aminotransferase elevations without jaundice, which promptly fell to normal with discontinuation or switching to another antibiotic. Recurrence is common with retreatment using carbenicillin, but not with ticarcillin. A similar phenomenon occurs with intravenous oxacillin. Rare instances of idiosyncratic, clinically apparent cholestatic liver injury have been reported in persons receiving ticarcillin in combination with clavulanate, some of which resemble the rare idiosyncratic reactions that can occur with many penicillins and which resemble the cholestatic liver injury that occurs after amoxicillin/clavulanate. |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)TicarcillinDILI NegativeIntramuscularIntravenousDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| 水環境危害等級（WGK） | 3 |
| 危険文句（R） |
用途
説明
Temocillin disodium is a broad-spectrum, β-lactamase resistant, injectable penicillin. High serum levels and a five hour half-life allow once or twice-daily dosing.